Recordati Industria Chimica e Farmaceutica S.p.A.
General ticker "RCDTF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $12.9B (TTM average)
Recordati Industria Chimica e Farmaceutica S.p.A. does not follow the US Stock Market performance with the rate: -30.5%.
Estimated limits based on current volatility of 0.0%: low 58.00$, high 58.00$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2026-05-19, amount 0.82$ (Y2.83%)
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [56.35$, 77.63$]
- 2026-12-31 to 2027-12-31 estimated range: [63.67$, 86.09$]
Financial Metrics affecting the RCDTF estimates:
- Negative: with PPE of 18.6 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 27.49 > 18.65
- Positive: 19.10 < Shareholder equity ratio, % of 36.55 <= 42.34
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.79 > 6.08
- Positive: 0.30 < Operating cash flow per share per price, % of 5.19
- Positive: Industry earnings per price (median), % of 6.62 > 4.29
- Positive: -4.44 < Investing cash flow per share per price, % of -0.70
Short-term RCDTF quotes
Long-term RCDTF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €2,082.33MM | €2,341.56MM | €2,618.38MM |
| Operating Expenses | €1,524.32MM | €1,702.70MM | €1,898.64MM |
| Operating Income | €558.01MM | €638.86MM | €719.74MM |
| Non-Operating Income | €-66.97MM | €-91.67MM | €-138.47MM |
| Interest Expense | €74.86MM | €81.55MM | €99.29MM |
| R&D Expense | €255.75MM | €286.03MM | €340.95MM |
| Income(Loss) | €491.04MM | €547.18MM | €581.27MM |
| Taxes | €101.82MM | €130.68MM | €137.65MM |
| Net Income(Loss)* | €389.21MM | €416.51MM | €443.62MM |
| Stockholders Equity | €1,686.39MM | €1,876.81MM | €1,919.77MM |
| Inventory | €404.83MM | €506.45MM | €539.80MM |
| Assets | €4,208.13MM | €5,134.45MM | €5,252.27MM |
| Operating Cash Flow | €485.32MM | €569.92MM | €596.90MM |
| Capital expenditure | €383.26MM | €851.16MM | €85.12MM |
| Investing Cash Flow | €-379.62MM | €-844.94MM | €-80.84MM |
| Financing Cash Flow | €-168.91MM | €372.11MM | €-407.02MM |
| Earnings Per Share** | €1.86 | €2.02 | €2.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.